A Hyderabad pharmaceutical formulation plant retrofitted protection settings, hardware and PPE across 14 substations entirely within a planned 14-day shutdown — ahead of a USFDA inspection. Zero schedule slip. Zero observations.
A mid-sized Indian pharmaceutical formulation plant in the Hyderabad cluster, supplying regulated US and EU markets, was scheduled for a USFDA inspection in 90 days. An internal EHS audit had flagged electrical safety as a likely observation. The plant electrical HOD had budget — but only one window: the next planned 14-day shutdown. The full retrofit (modelling, mitigation, hardware, hazard labels, training) had to land in that window or wait six months.
For a regulated arc flash risk assessment at a pharmaceutical site, six months is not an option. A USFDA observation on plant electrical safety can delay product approvals — and the cost of inaction is measured in months of lost revenue, not premium adjustments.
Pharmaceutical plants are not heavy-current sites in the way refineries or smelters are — but they carry their own arc flash risk profile. Granulation, blending, fluid-bed drying and tablet-compression areas have densely-packed MV motors and frequency drives. Schedule M and USFDA expectations include documented electrical safety as part of GMP infrastructure compliance. A USFDA Form 483 observation on plant safety can delay product approvals — the cost of inaction is measured in months of revenue, not premium adjustments.
The deliverable had to satisfy USFDA inspectors (focused on GMP rigour), the Indian Factory Inspector (focused on Factory Act §40 occupier liability), and the parent insurer (focused on documented arc flash hazard mitigation). One file. Three regulatory lenses.
Phases 1–3 (Discovery, Modelling, Risk Assessment) were completed before the shutdown started. The 14-day window was reserved exclusively for Phase 4 (Mitigation) and Phase 5 (labels, walk-down, sign-off).
Single-line diagrams reconciled across all 14 substations. ETAP model built. Incident energy calculated per IEEE 1584 (2018). Mitigation strategy locked. Hardware (4 arc-flash relays, 2 trip-rated fuses) ordered ahead of shutdown.
New protection settings deployed substation-by-substation. Selectivity verified panel-by-panel — no nuisance trips on re-energisation, no upstream coordination issues.
Arc-flash relays installed on 4 highest-energy buses identified by the IEEE 1584 study. Bay-by-bay re-energisation with arc-flash readings re-verified after each install.
NFPA 70E hazard labels printed and applied at every panel. Compliance file finalised with USFDA-format cross-references and Schedule M section-by-section mapping.
Two-day classroom + walk-the-floor training for 56 plant electrical and EHS staff. Re-study cycle agreed with the plant electrical HOD as part of the deliverable.
How the 6-Phase methodology was front-loaded so the shutdown window was used only for irreducible on-site work.
14 substations modelled in ETAP from reconciled SLDs, including all 415 V LV panels and 11 kV HV switchgear. Source-to-fault impedance verified against utility short-circuit data.
Incident energy calculated at every modelled bus per IEEE 1584-2018, including arc-blast distance and electrode configuration adjustments. PPE category assigned per NFPA 70E (2021).
4 dedicated arc-flash relays installed at the 4 highest-energy buses, with light-detection sensors targeting tripping in <2.5 ms. Cuts incident energy by an order of magnitude.
Pickup and time-dial settings re-tuned across feeders to clear faults faster while keeping selectivity intact. Selectivity verified panel-by-panel during shutdown.
Hazard labels printed in field with calculated incident energy, PPE category, working distance and approach boundaries — applied at every panel during the shutdown window.
Plant electrical & EHS staff trained on the new arc flash labels, PPE matrix, and energised-work protocols. Re-study cycle agreed and documented.
Verified by client electrical and EHS heads before USFDA inspection sign-off.
Average incident energy across modelled buses — at or above NFPA 70E PPE Category 3 on 9 of 14 buses.
48% average reduction. Routine switching downgraded to PPE Category 2. Documented and labelled at every panel.
11.2 → 5.8 cal/cm² across 14 modelled buses.
9 buses above NFPA Cat-2 cut down to 1.
14 days planned. 14 days actual. Plant restart on time.
Inspection closed clean on electrical safety.
One compliance file. Three audiences. Built for USFDA inspection, Factory Inspector audit and the parent insurer's underwriting checklist.
| Layer | Standards / References |
|---|---|
| Global standards | NFPA 70E (2021) · IEEE 1584 (2018) |
| Indian regulatory anchors | CEA Regulations 2010 · Factory Act 1948 §40 · IE Rules 1956 · IS 13408 |
| Sectoral overlay | USFDA cGMP · Schedule M (Drugs & Cosmetics Rules) · Insurer underwriting checklist |
| Measure | As-Found | Post-Retrofit | Change |
|---|---|---|---|
| Average incident energy across modelled buses | 11.2 cal/cm² | 5.8 cal/cm² | ↓ 48% |
| Buses above NFPA Cat-2 threshold | 9 | 1 | ↓ 89% |
| Shutdown window used | 14 days planned | 14 days actual | 0 slip |
| USFDA inspection outcome | — | No observation on electrical safety | Clean |
| Compliance file reuse | 1 audience | 3 audiences (USFDA, Factory Inspector, Insurer) | 3× |
The USFDA inspection closed with zero observations in the electrical-safety area. The compliance file was reused for the parent group's annual EHS audit and for the next insurance renewal — a single artefact serving three audiences. The plant electrical HOD reported the project as a category-defining example of "shutdown-window engineering."
Six questions we hear most often from pharma electrical & EHS leaders before they sign off on a study.
Pharmaceutical plants run densely-packed MV motors, frequency drives and process heaters across granulation, blending, fluid-bed drying and tablet-compression areas. Schedule M and USFDA expectations include documented electrical safety as part of GMP infrastructure compliance — a missing arc flash study is a likely Form 483 observation that can delay product approvals.
An electrical safety audit is a top-to-bottom check of compliance with statutory and standard requirements (CEA Regulations, IS 13234, etc.). An arc flash study is a quantitative engineering exercise — it models short-circuit current, calculates incident energy per IEEE 1584 and prescribes mitigation (settings + hardware + PPE) per NFPA 70E. The arc flash study is typically a deliverable inside the broader audit.
A 14-substation pharma formulation plant typically takes 8–12 weeks end to end: 6 weeks of pre-work (SLD reconciliation, ETAP modelling, IEEE 1584 calculations, mitigation strategy) and a 14-day shutdown for relay setting changes, hardware retrofit, hazard labelling and team training. Phasing depends on shutdown windows.
Global standards: NFPA 70E (2021 edition) and IEEE 1584 (2018 edition). Indian regulatory anchors: CEA Regulations 2010, Factory Act 1948 §40, IE Rules 1956 and IS 13408. Sectoral overlay: USFDA cGMP, Schedule M of the Drugs & Cosmetics Rules and the parent insurer's underwriting checklist — one compliance file, three regulatory lenses.
No — the retrofit is engineered to fit inside a planned shutdown. Phases 1–3 (Discovery, Modelling, Risk Assessment) are completed before shutdown using as-found data and SLDs. Only Phase 4 (Mitigation — relay settings + hardware) and Phase 5 (labels, walk-down, sign-off) are executed during the shutdown window. Production stays unaffected outside the planned outage.
USFDA inspectors are interested in documented, repeatable electrical safety practice as part of GMP infrastructure compliance — not in the arc flash study itself. The deliverable is structured to satisfy three audiences in one file: USFDA inspectors (GMP rigour), the Indian Factory Inspector (Factory Act §40 occupier liability) and the parent insurer (documented arc flash hazard mitigation).
We have run shutdown-window arc flash retrofits across the Hyderabad, Vizag, Vadodara and Bengaluru pharma clusters. Tell us your window and we'll come back with a phased plan within 48 hours — complimentary scoping call.